1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow 18F-NOTA-ABY-030: new trials by email Literature Review of 18F-NOTA-ABY-030 trials Research Report on 18F-NOTA-ABY-030
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET) - SCC - Squamous Cell Carcinoma, Radiotracer | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-04-24 | 2026-05-11 |
Carcinoma, Squamous Cell (1) · Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Vanderbilt-Ingram Cancer Center (1)
United States (1)